WAVE LIFE SCIENCES Towards the Clinic: Spotlight on RNA Editing for AATD Virtual event | September 28, 2022 Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing there ...

Wave Life Sciences Ltd. (NASDAQ:WVE) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President and Chief Executive Officer Mike Panzara - Chief Medical Officer Head, Therapeutics Discovery and Development Chandra Vargeese - Chief Technology Officer, Head of Platform Discovery Sciences Kyle Moran - Chief Financial Officer Conference Call Participants Salim Syed - Mizuho Luca Issi - RBC Mary Hodge - Truist Operator Good morn ...

| --- | --- | --- | --- | |-------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Wave Life Sciences Second Quarter 2022 Earnings | | | | | August 11, 2022 | | | | Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, busine ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore (State or other jurisd ...

Wave Life Sciences Corporate Presentation May 12, 2022 WAVE Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing thereof, competitive position, potential growth oppor ...

Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President and Chief Executive Officer Mike Panzara - Chief Medical Officer, Head, Therapeutics Discovery and Development Kyle Moran - Chief Financial Officer Conference Call Participants Joon Lee - Truist Securities Salim Syed - Mizuho Lisa Walter - RBC Alex Thompson - Stifel Mani Foroohar - SVB Securities Suji Jeong - Jefferies Operator Good ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore (State or other jurisdiction of incorporation or organization) Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For th ...

Chemically optimized stereopure oligonucleotides direct ADAR- mediated RNA editing Paloma H Giangrande, PhD Vice President, Platform Discovery Sciences Biology Oligonucleotides & Precision Therapeutics March 15-16, 2022 Forward looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business str ...

WAVE | --- | --- | --- | --- | --- | --- | |--------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | Wave Life Sciences | | | | | | | Corporate Presentation March 3, 2022 | | | | | | Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studi ...

Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2021 Earnings Conference Call March 3, 2022 8:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President and Chief Executive Officer Paloma Giangrande - Vice President, Biology and Platform Development Mike Panzara - Chief Medical Officer, Head, Therapeutics Discovery and Development Kyle Moran - Chief Financial Officer Conference Call Participants Salim Syed - Mizuho Mani Foroohar - SVB Securities Luca Issi - RBC Capital Operator Good ...